We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Catalent Inc | NYSE:CTLT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.06 | 0.11% | 55.91 | 56.13 | 55.75 | 55.75 | 218,462 | 15:50:25 |
From May 2019 to May 2024
By Colin Kellaher
Catalent Inc. on Wednesday said it will serve as a manufacturer for Johnson & Johnson's lead vaccine candidate for Covid-19.
The Somerset, N.J., contract drug maker said it will prepare for large-scale commercial manufacturing of the vaccine at its plant in Bloomington, Ind.
The company said it will invest jointly with J&J to accelerate rapid scale-up of segregated manufacturing capacity over the coming months to support dedicated production of the vaccine.
Catalent said it plans to hire about 300 new employees at the site starting in July 2020 to meet around-the-clock manufacturing schedules by January 2021.
Johnson & Johnson, which was among the first companies to announce a Covid-19 vaccine development program back in January, has said it aims to supply more than one billion doses of the vaccine globally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 29, 2020 09:17 ET (13:17 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Catalent Chart |
1 Month Catalent Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
